+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Extremely short telomeres and high telomerase activity in T-cell prolymphocytic leukemia (T-PLL): An optimal target for telomerase inhibition with GRN163L?

Extremely short telomeres and high telomerase activity in T-cell prolymphocytic leukemia (T-PLL): An optimal target for telomerase inhibition with GRN163L?

Journal of Clinical Oncology 26(15_suppl): 7061-7061

NlmCategory="UNASSIGNED">7061 Background: T-cell prolymphocytic leukemia (T-PLL) is an uncommon aggressive lymphoproliferative disease characterized by the expansion of a T-cell clone. We recently reported that leukemic T-PLL cells have extremely short telomeres (n=11, mean ± sd: 1.53 kb ± 0.65 kb) and high levels of telomerase activity (Roeth et al., 2007). We hypothesized that such cells have telomeres that are very close to critically short lengths and thus could be sensitive to telomerase inhibition with high sensitivity and short lag times. Our aim was to investigate the effect of the selective telomerase inhibitor GRN163L on survival of leukemic cells from T-PLL patients in short-term culture with detection of cell apoptosis by FACS-analysis using Annexin V-PI double staining. Telomere lengths of subsets of leukocytes from the peripheral blood of patients with T-PLL were determined by the automated flow-FISH and telomerase activity was measured by the TRAP-assay. The leukemic cells of these T-PLL patients had short telomere lengths and high telomerase activity. We observed a dose-dependent cytotoxicity in T-PLL cell cultures with GRN163L. Viable cells as a percentage of untreated controls (viability index) after 7 days of cell culture with 0, 1, 3, 10 μM GRN163L were as follows (% mean ± sd, (t-test p-value versus control)): 100 ± 0, 57.3 ± 17.5 (p=0.024), 37.4 ± 25.0 (p=0.022), 25.3 ± 20.0 (p=0.008), respectively, (n=4). No effect on viability was observed in normal, unstimulated T-cells after 7 days with 0, 1, 3, 10 μM GRN163L. Viability indices for normal T- cells were as follows: (% mean ± sd) 100 ± 0.0, 97.9 ± 1.7, 102.4 ± 9.4, 95.1 ± 4.7, respectively, (n=3). In addition, a dose-dependent increase of apoptotic cells with the telomerase inhibitor GRN163L by Annexin V-PI double staining was observed. A mismatch control oligonucleotide at 10 μM had no significant effect on viability of leukemic cells. GRN163L is active in T-PLL cells in vitro and leads to rapid cytotoxicity. Targeting telomerase and telomeres therefore seems an attractive strategy for the future treatment of this disease. These results provide strong rationale for a planned clinical trial of GRN163L in patients with T-PLL. [Table: see text].

(PDF emailed within 1 workday: $29.90)

Accession: 057851097

Download citation: RISBibTeXText

PMID: 27949627

Related references

Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia (Basingstoke) 21(12): 2456-2462, 2007

Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells. Cancer Research 61(14): 5580-5586, 2001

Telomerase inhibition in a mouse cell line with long telomeres leads to rapid telomerase reactivation. Experimental Cell Research 314(3): 668-675, 2007

Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 93(10): 3950-3957, 2008

Novel and potent telomerase antagonist (GRN163L) inhibits telomerase activity, resulting in telomere shortening and apoptosis of multiple myeloma cells. Journal of Clinical Oncology 23(16_suppl): 6605-6605, 2016

Long-term effects of short hairpin RNA-targeted human telomerase reverse transcriptase on suppression of SGC-7901 cell proliferation by inhibition of telomerase activity. Oncology Reports 19(2): 575-581, 2008

Telomeres, telomerase, and telomerase inhibition: Clinical implications for cancer. Journal of the American Geriatrics Society 51(1): 116-122, January, 2003

Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clinical Cancer Research 2(5): 799-803, 1996

Recombination can either help maintain very short telomeres or generate longer telomeres in yeast cells with weak telomerase activity. Eukaryotic Cell 10(8): 1131-1142, 2011

Telomere dynamics in cells with introduced telomerase: a rapid assay for telomerase activity on telomeres. Molecular Cell Biology Research Communications 3(5): 312-318, 2000

Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 21(54): 8262-8271, 28 November, 2002

Ectopic expression of human telomerase RNA component results in increased telomerase activity and elongated telomeres in bovine blastocysts. Biology of Reproduction 87(4): 95-95, 2013

Live cell imaging of telomerase RNA dynamics reveals cell cycle-dependent clustering of telomerase at elongating telomeres. Molecular Cell 44(5): 819-827, 2012

Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Research 64(14): 4833-4840, 2004

Homoharringtonine down-regulates telomerase reverse transcriptase expression and telomerase activity in human leukemia cell line. Blood 98(11 Part 2): 178b-179b, November 16, 2001